68Ga-PSMA PET in the Renal Cell Carcinoma

Launched by XIJING HOSPITAL · Jul 22, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a special imaging test called 68Ga-PSMA PET to see how well it can detect cancer spread in patients with advanced renal cell carcinoma, which is a type of kidney cancer. The researchers want to find out if this new imaging test is more effective than the current method, which is a contrast-enhanced CT scan. They are also interested in whether the results of the 68Ga-PSMA PET scan could change the treatment plans for patients.

To participate in the trial, you must be between the ages of 65 and 74 and have been diagnosed with stage III or IV renal cell carcinoma that shows signs of metastasis (cancer spread) on a CT scan. You should be able to undergo the imaging test within 6 weeks of your diagnosis and be willing to sign a consent form to join the study. If you join, you can expect to have the PET scan done, and the results will help doctors understand more about your condition and possibly influence your treatment options. It’s important to note that patients under 18, those with certain health issues, or those who have had other cancers recently may not be eligible for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 2017 AJCC renal cell carcinoma TNM stage III, IV lesions;
• • In contrast-enhanced CT staging, suspicious metastases were found;
• • There were no known peripheral or central venous problems;
• • 68Ga PSMA PET / CT imaging can be performed within 6 weeks after the diagnosis of renal cell carcinoma;
• • Signed the informed consent form of voluntary participation in clinical trials.
• Exclusion Criteria:
• • Age ≤ 18 years old;
• • Can't stand lying flat in PET / CT examination;
• • There are contraindications for 68Ga PSMA ligands;
• • In the past two years, there was a history of other malignant tumors, or according to the doctor's research judgment, complications may occur and affect the normal operation of the test;
• • Renal function is impaired or hemodialysis is in progress.